跨膜蛋白79在肝细胞癌中的表达及临床意义

doi:10.3969/j.issn.1004-616x.2023.06.004

Abstract

Abstract: OBJECTIVE：To investigate expression of the transmembrane protein 79(TMEM79) in hepatocellular carcinoma(HCC)，and to analyze its correlations with clinicopathological characteristics and prognosis of the patients. METHODS：From May 2011 to August 2017，clinicopathological data of 95 patients in the Meizhou People--s Hospital with HCC who received radical surgical treatment were collected. Expression levels of TMEM79 were evaluated using immunohistochemistry. Relationships between TMEM79 expressions and clinicopathological factors were analyzed using the χ² test. Kaplan-Meier method and Log-rank test were performed to analyze the survival time. Cox proportional risk regression model was used to analyze prognostic factors. RESULTS：The expression levels of TMEM79 in HCC was significantly correlated with the differentiation degree of HCC (χ²=8.902；P<0.05). The overall survival times (OS) and the progression-free survival times (PFS) of the negative expression group was significantly prolonged comparing with the positive expression group (P<0.01). Positive expression of TMEM79 was a risk factor for postoperative recurrences and metastases in patients with stage Ⅰa-Ⅱa [HR=2.001，95%CI (1.152，3.476)，P<0.05]. Histological morphology with mass form predominantly [HR=3.090，95%CI(1.317，7.273)，P<0.05] and the positive expression levels of TMEM79 [HR=3.323，95%CI (1.652，6.683)，P<0.05] were independent factors affecting postoperative PFS and OS in HC C patients with stageⅠa-Ⅱa(P<0.05). CONCLUSION：Expression of the TMEM79 protein in HCC tissue was related to the degrees of HCC differentiation. The positive expression levels of TMEM79 were related to poor prognosis. Positive expression levels of TMEM79 protein can possibly be used as a predictive factor for postoperative HCC patients with stage Ⅰa-Ⅱa.

Key words: hepatocellular carcinoma, transmembrane protein 79, prognosis, clinical features

CLC Number:

R730.2

ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.

References

[1] 国家卫生健康委员会医政医管局. 国家卫生健康委办公厅关于印发原发性肝癌诊疗指南(2022年版)的通知[EB/OL].(2022-01-20). http://www.nhc.gov.cn/yzygj/s7659/202201/a01ceb75c62b486fa459e36ba0fdfdbc.shtml.
[2] 南月敏, 高沿航, 王荣琦, 等. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3):532-542.
[3] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南-2022[M]. 北京:人民卫生出版社, 2022.
[4] SCHMIT K, MICHIELS C. TMEM proteins in cancer:a review[J]. Front Pharmacol, 2018, 9:1345.
[5] OβHURLEY G, BUSCH C, FAGERBERG L, et al. Analysis of the human prostate-specific proteome defined by transcriptomics and antibody-based profiling identifies TMEM79 and ACOXL as two putative, diagnostic markers in prostate cancer[J]. PLoS One, 2015, 10(8):e0133449.
[6] MARX S, DAL MASO T, CHEN J W, et al. Transmembrane (TMEM) protein family members:poorly characterized even if essential for the metastatic process[J]. Semin Cancer Biol, 2020, 60:96-106.
[7] JIANG X Y, WANG L, LIU Z Y, et al. TMEM48 promotes cell proliferation and invasion in cervical cancer via activation of the Wnt/β-catenin pathway[J]. J Recept Signal Transduct Res, 2021, 41(4):371-377.
[8] TIAN J, SUN L, WAN L S, et al. TMEM44 as a novel prognostic marker for kidney renal clear cell carcinoma is associated with tumor invasion, migration and immune infiltration[J]. Biochem Genet, 2023. doi:10.1007/s10528-023-10466-x.
[9] YE Z H, XIA Y Q, LI L, et al. Effect of transmembrane protein 100 on prostate cancer progression by regulating SCNN1D through the FAK/PI3K/AKT pathway[J]. Transl Oncol, 2023, 27:101578.
[10] CHEN J P, WANG D D, CHEN H Q, et al. TMEM196 inhibits lung cancer metastasis by regulating the Wnt/β-catenin signaling pathway[J]. J Cancer Res Clin Oncol, 2023, 149(2):653-667.
[11] ZHANG X L, HE Y, JIANG Y, et al. TMEM229A suppresses non-small cell lung cancer progression via inactivating the ERK pathway[J]. Oncol Rep, 2021, 46(2):176.
[12] DUAN J C, QIAN Y W, FU X H, et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma[J]. Aging, 2021, 13(4):5585-5606.
[13] ZHANG L, LIU S Y, YANG X, et al. TMEM206 is a potential prognostic marker of hepatocellular carcinoma[J]. Oncol Lett, 2020, 20(5):174.
[14] CHEN D S, LOU Y C, LU J, et al. Characterization of the clinical significance and immunological landscapes of a novel TMEMs signature in hepatocellular carcinoma and the contribution of TMEM201 to hepatocarcinogenesis[J]. Int J Mol Sci, 2023, 24(12):10285.
[15] EMRICK J J, MATHUR A, WEI J, et al. Tissue-specific contributions of Tmem79 to atopic dermatitis and mast cell-mediated histaminergic itch[J]. Proc Natl Acad Sci U S A, 2018, 115(51):E12091-E12100.
[16] HE S, LYU F Q, LOU L X, et al. Anti-tumor activities of Panax quinquefolius saponins and potential biomarkers in prostate cancer[J]. J Ginseng Res, 2021, 45(2):273-286.

Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[2]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[3]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[4]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[5]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[6]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[7]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[8]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[9]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[10]	HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.
[11]	XU Hao, HU Bichuan, ZOU Wei, DUAN Yabin. Identification of prognostic factors among patients with stage Ⅲ gastric cancer undergoing radical resection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 30-36.
[12]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[13]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[14]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[15]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.